YS Biopharma Co. Ltd. Ordinary Shares

A family-run bakery or artisan workshop owner shaking hands with a relationship banker.

Company profile

About

YS Biopharma (NASDAQ: YS) is a biopharma company listed on the NASDAQ stock exchange. The company focuses on developing, manufacturing, and commercializing innovative vaccines and therapeutic products. Key projects include its flagship PIKA adjuvant technology and a pipeline of next-generation vaccines targeting infectious diseases like COVID-19 and rabies. The main objectives are to improve global health through cutting-edge vaccines and to expand its product portfolio via research and development. YS aims to leverage its scientific expertise to address unmet medical needs and enhance the effectiveness of existing and new vaccines.

Snapshot

2010Year founded

773Employees

Beijing, ChinaHead office

Loading Map...

Global footprint

Operations

All Locations

People’s Republic of China

Products and/or services of YS Biopharma Co. Ltd. Ordinary Shares

Pneumococcal Conjugate Vaccine: A key product designed to prevent pneumococcal infections, critical for immunization programs, particularly in children.
Ebola Vaccine: Focuses on providing a robust solution for Ebola virus prevention, pivotal for controlling outbreaks in affected regions.
Hepatitis B Vaccine: Essential for combating hepatitis B infections with strong immunogenicity, aimed at lowering global disease prevalence.
Rabies Vaccine: Offers reliable post-exposure prophylaxis against rabies, vital for both human and veterinary use.
Animal Vaccines: Broad range of vaccines targeting livestock diseases, enhancing animal health and agricultural productivity.
Research and Development: Continuous efforts in innovative vaccine development, emphasizing future health solutions and technological advancements.